Amgen Inc. turned in second-quarter adjusted earnings per share of 62 cents, topping consensus estimates and surging 27 percent higher than a year ago. (BioWorld Today)

Aranesp, Enbrel, Neulasta Sales Drive Amgen To Beat Estimates

July 26, 2004

By Aaron Lorenzo

No Comments

Amgen Inc. turned in second-quarter adjusted earnings per share of 62 cents, topping consensus estimates and surging 27 percent higher than a year ago. (BioWorld Today)

Specialty Pharma Firm Auxilium Raises $41.25M In Initial Offering

July 26, 2004

By Aaron Lorenzo

No Comments

Chiron, MedImmune, Serono Report Earnings For Quarter

July 23, 2004

By Aaron Lorenzo

No Comments

Chiron, MedImmune, Serono Report Earnings For Quarter

July 23, 2004

By Aaron Lorenzo

No Comments

AGY In-Licenses Clinical CNS Compound From M's Science

July 21, 2004

By Aaron Lorenzo

No Comments

View All Articles by Aaron Lorenzo

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Aaron Lorenzo

ARTICLES

With Antegren Launch Expected, Biogen Idec Tops 2Q Estimates

With Antegren Launch Expected, Biogen Idec Tops 2Q Estimates

MannKind IPO Prices Within Range; Shares Close Higher

Specialty Pharma Firm Auxilium Raises $41.25M In Initial Offering

Aranesp, Enbrel, Neulasta Sales Drive Amgen To Beat Estimates

Aranesp, Enbrel, Neulasta Sales Drive Amgen To Beat Estimates

Specialty Pharma Firm Auxilium Raises $41.25M In Initial Offering

Chiron, MedImmune, Serono Report Earnings For Quarter

Chiron, MedImmune, Serono Report Earnings For Quarter

AGY In-Licenses Clinical CNS Compound From M's Science

Today's news in brief

Today's news in brief

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

Australia’s Celosia heads toward clinic with gene therapy for ALS

Sangamo stock plunges as Pfizer leaves hemophilia partnership